Carbetapentane attenuates kainate-induced seizures via sigma-1 receptor modulation

Life Sci. 2001 Jul 13;69(8):915-22. doi: 10.1016/s0024-3205(01)01181-x.

Abstract

We examined the effects of a non-opioid antitussive, carbetapentane (CB) on kainic acid (KA)-induced neurotoxicity in rats. KA administration (10 mg/kg, i.p.) produced robust behavioral convulsions lasting 4 to 5 h. CB (12.5 and 25 mg/kg. i.p.) pretreatment consistently and in a dose-dependent manner reduced the KA-induced seizures, mortality, and marked loss of cells in regions CA1 and CA3 of the hippocampus. Consistently, CB pretreatment also significantly attenuated the KA-induced increase in Fos-related antigen immunoreactivity in the hippocampus. In contrast, pretreatment with the sigma-1 receptor antagonist BD1047 (1 and 2 mg/kg, i.p.) blocked, in a dose-related manner, the neuroprotection afforded by CB. These results suggest that CB provides neuroprotection against KA insult via sigma-1 receptor modulation.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Benzoxazines
  • Brain / drug effects
  • Brain / metabolism
  • Cells, Cultured
  • Cyclopentanes / pharmacology*
  • Drug Interactions
  • Immunohistochemistry
  • Kainic Acid*
  • Male
  • Oxazines
  • Rats
  • Rats, Sprague-Dawley
  • Receptors, sigma / metabolism*
  • Seizures / chemically induced*
  • Sigma-1 Receptor

Substances

  • Benzoxazines
  • Cyclopentanes
  • Oxazines
  • Receptors, sigma
  • cresyl violet
  • carbetapentane
  • Kainic Acid